Search - tctmd.com

Displaying 201 - 220 of 329

Sort: Relevancy | Date

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

Presenter: Andreas Baumbach, David Hildick-Smith, Ted Feldman

November 01, 2016

Presentation TCT 2016

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Presenter: Zahid Amin, Jacqueline Saw, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs

Presenter: Vivek Y. Reddy

October 31, 2016

Presentation TCT 2016

Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur)

Presenter: Glenn Van Langenhove

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Jean-Claude Laborde, Azfar G. Zaman

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Advertisement

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs

Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur)

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content